WO2014140680A8 - Schéma posologique de l'utilisation du celgosivir comme traitement antiviral contre l'infection par le virus de la dengue - Google Patents

Schéma posologique de l'utilisation du celgosivir comme traitement antiviral contre l'infection par le virus de la dengue Download PDF

Info

Publication number
WO2014140680A8
WO2014140680A8 PCT/IB2013/001634 IB2013001634W WO2014140680A8 WO 2014140680 A8 WO2014140680 A8 WO 2014140680A8 IB 2013001634 W IB2013001634 W IB 2013001634W WO 2014140680 A8 WO2014140680 A8 WO 2014140680A8
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
celgosivir
virus infection
dosing regimen
infection
Prior art date
Application number
PCT/IB2013/001634
Other languages
English (en)
Other versions
WO2014140680A1 (fr
Inventor
Subhash Vasudevan
Abhay RATHORE
Cynthia Sung
Satoru Watanabe
Jenny LOW
Eng Eong Ooi
Original Assignee
National University Of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Of Singapore, Singapore Health Services Pte Ltd filed Critical National University Of Singapore
Publication of WO2014140680A1 publication Critical patent/WO2014140680A1/fr
Publication of WO2014140680A8 publication Critical patent/WO2014140680A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement d'une infection par le virus de la dengue (DENV) chez un sujet humain, comprenant l'administration au sujet humain d'une composition de formule (I), ou d'une composition pharmaceutique comprenant une composition de formule (I) : Une composition de formule (I) peut être administrée dans les 48 à 72 heures suivant l'apparition de la fièvre due à l'infection par la dengue, puis toutes les 0,6 à 1-2 heures jusqu'à ce qu'il y ait une amélioration au niveau de l'infection. Les méthodes de l'invention peuvent être utilisées pour traiter les infections virales DENV 1-4 primaire et secondaire.
PCT/IB2013/001634 2013-03-15 2013-07-26 Schéma posologique de l'utilisation du celgosivir comme traitement antiviral contre l'infection par le virus de la dengue WO2014140680A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798100P 2013-03-15 2013-03-15
US61/798,100 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014140680A1 WO2014140680A1 (fr) 2014-09-18
WO2014140680A8 true WO2014140680A8 (fr) 2015-06-25

Family

ID=51535932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/001634 WO2014140680A1 (fr) 2013-03-15 2013-07-26 Schéma posologique de l'utilisation du celgosivir comme traitement antiviral contre l'infection par le virus de la dengue

Country Status (2)

Country Link
AU (1) AU2013203400B2 (fr)
WO (1) WO2014140680A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010781A1 (fr) * 2022-07-05 2024-01-11 60 Degrees Pharmaceuticals Llc Méthodes de traitement d'une infection respiratoire à l'aide d'analogues de castanospermine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501352D0 (en) * 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope

Also Published As

Publication number Publication date
AU2013203400A1 (en) 2014-10-02
WO2014140680A1 (fr) 2014-09-18
AU2013203400B2 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
SI2709613T1 (en) Procedures for the treatment of HCV
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
MY194294A (en) Novel viral replication inhibitors
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
RU2014117294A (ru) 4,6-ди(3,12-диаза-6,9-диазониадиспиро[5.2.5.2]гексадекан-1-ил)-2-метил-5-нитропиримидин тетрахлорид дигидрохлорид гексагидрат для лечения герпетической инфекции, фармацевтическая композиция для местного применения
WO2014140680A8 (fr) Schéma posologique de l'utilisation du celgosivir comme traitement antiviral contre l'infection par le virus de la dengue
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
UA90646C2 (ru) Способ лечения часто рецидивирующей хронической герпетической инфекции, вызванной вирусом герпеса простого и и ии типов

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13877612

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13877612

Country of ref document: EP

Kind code of ref document: A1